keyword
MENU ▼
Read by QxMD icon Read
search

Sandostatin LAR

keyword
https://www.readbyqxmd.com/read/27697899/somatostatin-analogues-in-acromegaly-and-gastroenteropancreatic-neuroendocrine-tumours-past-present-and-future
#1
REVIEW
Kjell Öberg, Steven W J Lamberts
Acromegaly is a hormonal disorder that arises when the pituitary gland secretes excess growth hormone (GH), which in turn stimulates a concomitant increase in serum insulin-like growth factor 1 (IGF-1) levels. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) constitute a heterogeneous group of tumours that can secrete serotonin and a variety of peptide hormones that may cause characteristic symptoms known as carcinoid syndrome or other symptoms and hormonal hypersecretion syndromes depending on the tumour's site of origin...
December 2016: Endocrine-related Cancer
https://www.readbyqxmd.com/read/27040814/pharmacokinetic-and-pharmacodynamic-study-of-a-phospholipid-based-phase-separation-gel-for-once-a-month-administration-of-octreotide
#2
Mengxin Wang, Fengying Shan, Yang Zou, Xun Sun, Zhi-Rong Zhang, Yao Fu, Tao Gong
As a natural somatostatin analog, octreotide acetate (OCT) has been extensively used in cancer treatment and growth hormone related diseases. The clinical application of OCT, however, is greatly limited by its short half-life, rapid elimination and clearance in vivo. In the current study, a high content phospholipid-based phase separation gel platform (PPSG) was presented, which could be injected in the soluble state and underwent rapid phase-separation into a gel-like implant after a single subcutaneous injection...
May 28, 2016: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/26838946/problems-of-diagnostic-assessment-in-advanced-pancreatic-neuroendocrine-neoplasm-and-treatment-implications-a-case-report-and-literature-review
#3
Bartosz Szymanowski, Renata Duchnowska, Marek Bilski, Grażyna Łapińska, Beata Hryciuk, Grzegorz Kamiński, Cezary Szczylik
We are reporting a case of a 55-year-old woman who was diagnosed as having a non-functioning pancreatic neuroendocrine neoplasm (NF-PNEN), the World Health Organization (WHO) low grade (G1) with liver metastases. In the staging process the positron emission tomography - computed tomography with Fluorine-18-Fluorodeoxyglucose (F-FDG PET-CT) and spiral CT then the gallium-DOTA-octreotate positron emission tomography - computer tomography (⁶⁸Ga-DOTATATE PET-CT) shown difference in burden of disease. In first line therapy, everolimus (Afinitor®, Novartis Pharma GmbH, Germany) at the oral dose of 10 mg once daily and octreotide long-acting release (Sandostatin LAR®) 30 mg i...
2016: Nuclear Medicine Review. Central & Eastern Europe
https://www.readbyqxmd.com/read/26609262/effects-of-combination-therapy-somatostatin-analogues-and-dopamine-agonists-on-gh-and-igf1-levels-in-acromegaly
#4
Ana Valea, Cristina Ghervan, Mara Carsote, Andra Morar, Iulia Iacob, Florica Tomesc, Dan Dumitru Pop, Carmen Georgescu
BACKGROUND AND AIMS: Acromegaly is a complex endocrine disorder caused by excessive secretion of GH, secondary to a GH secreting pituitary adenoma or a mixed pituitary adenoma secreting GH and PRL. METHODS: The aim of this study was to evaluate the effects of combination therapy: dopamine agonist and somatostatin analogue on GH and IGF1 levels in a group of 30 patients with acromegaly. Cabergoline in a dose of 2 mg/week and 4 mg/week respectively was associated with Sandostatin LAR in a dose of 20 mg/month and 30 mg/months respectively...
2015: Clujul Medical (1957)
https://www.readbyqxmd.com/read/25958482/efficacy-of-long-acting-somatostatin-analogs-in-recurrent-variceal-bleeding-in-a-patient-with-pre-hepatic-portal-vein-thrombosis
#5
Tamara Alempijević, Ana Balović, Aleksandra Pavlović-Marković, Dino Tarabar, Miodrag Krstić, Predrag Miljić, Miloš Bjelović
INTRODUCTION: Bleeding from esophageal varices is a serious medical problem because of the risk of recurrent bleeding and high mortality rate (17-54%). Gastroesophageal varices develop in 50% of cirrhotic patients with portal hypertension, but can also develop in other pre- or post-hepatic causes of portal hypertension. CASE REPORT: We reported a 48-year-old female patient with portal hy- pertension caused by mesenterial vein thrombosis due to congenital thrombophilia...
March 2015: Vojnosanitetski Pregled. Military-medical and Pharmaceutical Review
https://www.readbyqxmd.com/read/25813261/-akromegaly-and-pharmacotherapy
#6
Helena Šiprová, Miroslav Souček
Acromegaly is a rare and serious disease. A successful and rational therapy of acromegaly ought to combine surgery, radiotherapy and pharmacotherapy. The submitted article presents a case of acromegaly that was only diagnosed at the stage when total pituitary adenoma removal was impossible. Even so, the long-term stabilisation of the disease was reached by way of repeated surgery through transfenoidal and transcranial approach, by linear accelerator radiation therapy and Leksell Gamma Knife radiotherapy and by pharmacotherapy with somatostatin analogon octreotide and growth hormone receptor antagonist pegvisomant...
February 2015: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/25692122/transfusion-free-radical-antegrade-modular-pancreaticosplenectomy-of-metastatic-neuroendocrine-tumor-of-the-pancreas-in-jehovah-s-witness-patient
#7
Young Bae Jeon, Sangchul Yun, Dongho Choi
In a popular sense, Jehovah's Witnesses (JW) have their creeds, one of which is refusal of blood transfusion. Such refusal may impinge on their proper management, especially in critical situations. We present a case of successful bloodless multimodality therapy, which was performed for a JW. The patient was a 49-year-old woman and JW who had general weakness 7 days before admission. She was diagnosed with a pancreatic neuroendocrine tumor (PNET) with hepatic metastases. Transcatheter arterial chemoembolization and Sandostatin LAR injection were performed, and then she was given a transfusion-free Radical antegrade modular pancreatosplenectomy sequentially...
February 2015: Annals of Surgical Treatment and Research
https://www.readbyqxmd.com/read/25404386/poor-pregnancy-outcome-after-octreotide-treatment-during-pregnancy-for-familial-hyperinsulinemic-hypoglycemia-a-case-report
#8
Gitte O Skajaa, Elisabeth R Mathiesen, Elisabeth Iyore, Henning Beck-Nielsen, Espen Jimenez-Solem, Peter Damm
BACKGROUND: Late familial hyperinsulinemic hypoglycemia is characterized by recurrent episodes of hypoglycemia and an inappropriate insulinemic response. Treatment with octreotide (somatostatin analogue) reduces the prevalence of clinical significant hypoglycemia and might be beneficial during pregnancy. To our knowledge this is the first report of a woman with late familial hyperinsulinemic hypoglycemia experiencing pregnancies with and without octreotide treatment. CASE PRESENTATION: A 35-year-old Caucasian woman known to suffer from late familial hyperinsulinemic hypoglycemia due to a well-known mutation in the insulin receptor gene has been pregnant 6 times...
2014: BMC Research Notes
https://www.readbyqxmd.com/read/24824963/treatment-with-octreotide-in-patients-with-well-differentiated-neuroendocrine-tumors-of-the-ileum-prognostic-stratification-with-ga-68-dota-tate-positron-emission-tomography
#9
Walter Koch, Christoph J Auernhammer, Julia Geisler, Christine Spitzweg, Clemens C Cyran, Harun Ilhan, Peter Bartenstein, Alexander R Haug
We investigated the use of Ga-68-DOTA-Tyr3-octreotate (Ga-68-DOTA-TATE) positron emission tomography (PET) and standardized uptake values (SUVs) to predict the effectiveness of treatment with the somatostatin analogue octreotide acetate (Sandostatin LAR) in patients with neuroendocrine tumors (NETs). Thirty patients with well-differentiated NETs of the ileum (grades G1 and G2) were studied with Ga-68-DOTA-TATE. The average SUV of a 50% isocontour volume of interest covering the lesion with maximum uptake (SUV mean) and the maximum SUV (SUV max) were determined...
2014: Molecular Imaging
https://www.readbyqxmd.com/read/23645293/pituitary-carcinoma-with-endolymphatic-sac-metastasis
#10
Irida Balili, Steven Sullivan, Paul Mckeever, Ariel Barkan
Pituitary carcinoma is characterized by the presence of a metastatic lesion(s) in a location non-contiguous with the original pituitary tumor. The mechanism(s) of malignant transformation are not known. A 15 year-old male was diagnosed in 1982 with a pituitary macroadenoma and acromegaly (random GH 67 ng/ml and no suppression by oral glucose). His prolactin was normal between 18 and 23 ng/ml. Transcranial resection in July 1983 was followed by radiation therapy. The tumor was immunopositive for GH and prolactin...
June 2014: Pituitary
https://www.readbyqxmd.com/read/23370660/capecitabine-and-temozolomide-captem-for-metastatic-well-differentiated-neuroendocrine-cancers-the-pancreas-center-at-columbia-university-experience
#11
Robert L Fine, Anthony P Gulati, Benjamin A Krantz, Rebecca A Moss, Stephen Schreibman, Dawn A Tsushima, Kelley B Mowatt, Richard D Dinnen, Yuehua Mao, Peter D Stevens, Beth Schrope, John Allendorf, James A Lee, William H Sherman, John A Chabot
PURPOSE: We evaluated the efficacy and safety of capecitabine and temozolomide (CAPTEM) in patients with metastatic neuroendocrine tumors (NETs) to the liver. This regimen was based on our studies with carcinoid cell lines that showed synergistic cytotoxicity with sequence-specific dosing of 5-fluorouracil preceding temozolomide (TMZ). METHODS: A retrospective review was conducted of 18 patients with NETs metastatic to the liver who had failed 60 mg/month of Sandostatin LAR™ (100%), chemotherapy (61%), and hepatic chemoembolization (50%)...
March 2013: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/23235517/treatment-of-multiple-endocrine-neoplasia-1-2-tumors-case-report-and-review-of-the-literature
#12
REVIEW
Anthony P Gulati, Benjamin Krantz, Rebecca A Moss, Wendy N Moyal, Dawn A Tsushima, Kelley B Mowatt, Stephen Schreibman, Robert L Fine
BACKGROUND: Neuroendocrine tumors are uncommon tumors that are histopathologically and biologically heterogeneous and include the multiple endocrine neoplasia (MEN) 1 and 2 syndromes. The morbidity of MEN-1 and MEN-2 is often due to the symptomatology of the endocrine hormones produced, and the mortality mainly occurs from hepatic dysfunction incurred by liver metastases. At present, there is essentially no effective cure once the tumor has metastasized to the liver. PATIENT: We present a patient with progressive, metastatic MEN-1 with the classic '3 P's' triad of neuroendocrine tumor of the pancreas, parathyroid adenoma and a pituitary adenoma...
2013: Oncology
https://www.readbyqxmd.com/read/23166456/decision-tree-model-for-health-economic-comparison-of-two-long-acting-somatostatin-receptor-ligand-devices-in-france-germany-and-the-uk
#13
Rémi Marty, Stéphane Roze, Hannah Kurth
BACKGROUND: Long-acting somatostatin receptor ligands (SRL) with product-specific formulation and means of administration are injected periodically in patients with acromegaly and neuroendocrine tumors. A simple decision-tree model aimed at comparing cost savings with ready-to-use Somatuline Autogel(®) (lanreotide) and Sandostatin LAR(®) (octreotide) for the UK, France, and Germany. The drivers of cost savings studied were the reduction of time to administer as well as a reduced baseline risk of clogging during product administration reported for Somatuline Autogel(®)...
2012: Medical Devices: Evidence and Research
https://www.readbyqxmd.com/read/23164993/somatostatin-receptor-scintigraphy-in-patients-with-metastatic-uveal-melanoma
#14
Matias E Valsecchi, Misti Coronel, Charles M Intenzo, Sung M Kim, Agnieszka K Witkiewicz, Takami Sato
As uveal melanoma originates in the neural crest, we aimed to explore whether somatostatin receptor (SSTR) expression is present and plays any role in these patients. Heavily pretreated metastatic uveal melanoma patients were tested with somatostatin receptor scintigraphy (SRS). Planar images of the whole body complemented by single-photon emission computed tomography on suspected sites were acquired between 4 and 24 h after an intravenous administration of 185-222 MBq (5-6 mCi) of indium-octeotride. SSTR expression in metastatic tissues was confirmed by immunohistochemistry...
February 2013: Melanoma Research
https://www.readbyqxmd.com/read/22572824/a-pilot-study-of-long-acting-octreotide-for-symptomatic-malignant-ascites
#15
RANDOMIZED CONTROLLED TRIAL
Aminah Jatoi, Jorge J Nieva, Rui Qin, Charles L Loprinzi, Edward J Wos, Paul J Novotny, Dennis F Moore, Rex B Mowat, Naftali Bechar, Eduardo R Pajon, Lynn C Hartmann
BACKGROUND: Effective, non-invasive, palliative strategies for symptomatic malignant ascites are unavailable. This trial explored whether octreotide, an inhibitor of vascular endothelial growth factor, a putative mediator of ascites, prolongs the interval to next paracentesis. METHODS: After a baseline paracentesis and a test of short-acting agent, patients with symptomatic ascites were randomly assigned to long-acting octreotide (Sandostatin LAR®) depot 30 mg intramuscularly every month versus 0...
2012: Oncology
https://www.readbyqxmd.com/read/22390555/octreotide-long-acting-repeatable-for-acromegaly
#16
REVIEW
Renato Cozzi, Roberto Attanasio
Acromegaly remains a therapeutic challenge for the endocrinologist. Among the available therapeutic options, octreotide long-acting repeatable (Sandostatin(®) LAR(®), Novartis) plays a chief role, both as a primary therapy and as an adjuvant treatment after unsuccessful surgery. A plethora of papers and a meta-analysis have demonstrated its efficacy in: control of clinical picture; achievement of safe growth hormone and normal age-matched IGF-I levels (both factors associated with restoration of normal life expectancy) in 60-70% of patients; control of tumor volume (with real shrinkage in over half of cases); and halt or reversal of most acromegaly-associated comorbidities...
March 2012: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/22380529/randomised-clinical-trial-the-safety-and-efficacy-of-long-acting-octreotide-in-patients-with-portal-hypertension
#17
RANDOMIZED CONTROLLED TRIAL
N Chandok, P S Kamath, A Blei, J Bosch, W Carey, N Grace, K V Kowdley, K Benner, R J Groszmann
BACKGROUND: It remains unclear whether a long-acting preparation of octreotide (Sandostatin LAR) can be safely used for portal hypertension in patients with compensated cirrhosis. AIM: To determine the safety and efficacy of LAR among patients with Child Pugh Class A or B cirrhosis and small oesophageal varices. METHODS: A randomised, double-blind, placebo-controlled study was conducted in 39 patients with cirrhosis and small oesophageal varices...
April 2012: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/22048969/successful-treatment-of-congenital-hyperinsulinism-with-long-acting-release-octreotide
#18
Kim-Hanh Le Quan Sang, Jean-Baptiste Arnoux, Asmaa Mamoune, Cécile Saint-Martin, Christine Bellanné-Chantelot, Vassili Valayannopoulos, Anais Brassier, Honorine Kayirangwa, Valérie Barbier, Christine Broissand, Jean-Roch Fabreguettes, Brigitte Charron, Jean-Christophe Thalabard, Pascale de Lonlay
CONTEXT: Congenital hyperinsulinism (HI) is a common cause of hypoglycemia in infancy. The medical treatment of diazoxide-unresponsive HI is based on a somatostatin analogue. OBJECTIVE: This study aims at replacing three daily s.c. octreotide (Sandostatin, Novartis) injections by a single and monthly i.m. injection of long-acting release (LAR) octreotide (Sandostatin LP, Novartis) in HI patients. SUBJECTS AND METHOD: LAR octreotide was injected every 4 weeks during 6 months and s...
February 2012: European Journal of Endocrinology
https://www.readbyqxmd.com/read/21955199/medical-treatment-of-recurrent-meningiomas
#19
REVIEW
Marc C Chamberlain, Jill S Barnholtz-Sloan
Meningiomas are the second most common primary brain tumor and are primarily treated with surgery (with or without embolization) and radiotherapy. Increasingly today, meningiomas undergo multiple resections and two radiotherapy treatments (either stereotactic or conventional external beam) before consideration for hormonal, chemotherapy or targeted therapy. The failure of hormonal and cytotoxic chemotherapy in the treatment of recurrent meningioma and increasing understanding of potential molecular targets in meningioma has resulted in multiple studies utilizing single-agent targeted therapy directed at biologically relevant signaling pathways, such as somatostatin (Sandostatin(®) LAR, SOM230c), PDGF (imatinib), EGF (erlotinib) and VEGF (sunitinib and vatalanib)...
October 2011: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/21948321/sustained-release-delivery-of-octreotide-from-biodegradable-polymeric-microspheres
#20
Yun-Seok Rhee, MinJi Sohn, Byung H Woo, B C Thanoo, Patrick P DeLuca, Heidi M Mansour
The study reports on the drug release behavior of a potent synthetic somatostatin analogue, octreotide acetate, from biocompatible and biodegradable microspheres composed of poly-lactic-co-glycolic acid (PLGA) following a single intramuscular depot injection. The serum octreotide levels of three Oakwood Laboratories formulations and one Sandostatin LAR(®) formulation were compared. Three formulations of octreotide acetate-loaded PLGA microspheres were prepared by a solvent extraction and evaporation procedure using PLGA polymers with different molecular weights...
December 2011: AAPS PharmSciTech
keyword
keyword
88409
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"